Lyra Says Phase 3 Trial of Nasal Implant for Chronic Rhinosinusitis Meets Endpoints

In This Article:

Lyra Therapeutics (LYRA) said Monday that a phase 3 trial of LYR-210 bioabsorbable nasal implant met

Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.